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Obesity and insulin resistance are important risk factors for major diseases such as metabolic syndrome, type 2 diabetes mellitus, 
and atherosclerotic cardiovascular disease. Chronic subclinical inflammation appears to underlie these disorders.  Increasing
evidence suggests that dysregulation of metabolically active adipose tissue contributes to systemic inflammation in part by secret-
ing higher concentrations of pro-inflammatory adipokines (a diverse set of bioactive proteins produced by adipose tissue). Some
adipokines act as endocrine factors directly enhancing systemic inflammation. Increased secretion of these adipokines results
from local adipose tissue inflammation that is mediated in part by autocrine and/or paracrine pathway.  Adipokine expression
and thus secretion are modulated by intercellular cross talk within adipose tissue, including that between adipocytes and mac-
rophages (and possibly mast cells), as well as by oxidative stress and activation of pro-inflammatory pathways such as nuclear
factor kappa B and mitogen-activated protein kinase pathways. These regulators of adipokine expression and secretion may serve 
as therapeutic targets for pharmacologic agents that ameliorate the above adipokine-related diseases. These agents include the 
widely used angiotensin II type 1 receptor blockers, inhibitors of angiotensin-converting enzyme, metformin, thiazolidinediones, 
statins, salicylates, as well as others yet to be developed. Biomed Rev 2006; 17: 63-72.
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INTRODUCTION
Obesity and insulin resistance are key features of the meta-
bolic syndrome (1) that increases the risk for development of 
diseases such as atherosclerotic cardiovascular disease (CVD) 
and type 2 diabetes mellitus (T2DM) (2). The rapidly increas-
ing prevalence of these disorders in the last decades poses 
a challenging healthcare burden in terms of the associated 
morbidity, mortality, and economic impact. Prevention and 
treatment of these disorders requires targeting their underly-
ing mechanisms. 
Chronic subclinical inflammation appears to underlie
obesity and insulin resistance as well as predict the develop-
ment of T2DM and/or CVD. This systemic inflammation is
characterized by elevated concentrations of various circulating 
pro-inflammatory proteins that act in an endocrine fashion. For
example, increased plasma interleukin-6 (IL-6) concentration 
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is associated with increased obesity (3), insulin resistance (4), 
severity of T2DM (5), and cardiovascular complications (6). 
Plasma concentration of a related pro-inflammatory chem-
okine, interleukin-8 (IL-8/CXCL8), increases with insulin 
resistance in abdominally obese male subjects (4) and with 
atherosclerotic plaque instability in coronary heart disease 
patients (7). Circulating concentrations of another pro-inflam-
matory protein, plasminogen activator inhibitor-1 (PAI-1), are 
also associated with insulin resistance (8), T2DM (9), and an 
increased risk for developing CVD (10). In addition, elevated 
concentrations of C-reactive protein (CRP), an acute phase 
protein, are similarly associated with poor glycemic control in 
T2DM (11), predict T2DM (8), and constitute a risk factor for 
ischemic stroke (12). C-reactive protein and serum amyloid A 
(SAA), another acute phase protein, predict CVD independ-
ently of each other (13), even though their serum concentra-
tions are correlated (14). Concentrations of SAA also correlate 
with obesity (15) and fasting insulin levels, indicating a link 
to insulin resistance (14).
In addition to the above endocrine factors, systemic concen-
trations of pro-inflammatory proteins that have generally been
considered to act in a paracrine fashion, such as the pleiotropic 
cytokine tumor necrosis factor-α (TNF-α) (16) and chemokine 
monocyte chemotactic protein-1 (MCP-1/CCL2) (17, 18), 
are also associated with both obesity and impaired insulin 
sensitivity. Furthermore, serum concentrations of TNF-α cor-
relate with those of CRP (19), predict CVD events (20), and 
are increased in subjects with T2DM (21). Similarly, plasma 
MCP-1 concentrations are elevated in patients with acute 
myocardial infarction (22) or acute coronary syndromes (23) 
compared to those with stable angina, while its concentrations 
in the latter subjects are higher still than those in people with 
angiographically normal coronary arteries (24). 
In contrast to the above pro-inflammatory proteins, plasma
concentrations of adiponectin, an anti-inflammatory protein,
inversely correlate with measures of obesity and insulin 
resistance in non-diabetic subjects (25). Low concentrations 
of adiponectin predict the progression of T2DM, with the 
high molecular weight form of adiponectin being a stronger 
predictor compared to total adiponectin (26). In addition, 
higher plasma adiponectin concentrations are associated with 
a lower risk of myocardial infarction independent of glycemic 
status (27). Taken together, the concerted actions of the above 
circulating pro- and anti-inflammatory proteins, along with
others yet to be discovered, appear critical in linking obesity 
and insulin resistance with T2DM and CVD. 
Adipose tissue may contribute to systemic inflammation as
described above by its secretion of pro- and anti-inflamma-
tory proteins, including cytokines, chemokines, acute phase 
reagents, and growth factors (25-30). These proteins are called 
adipokines to indicate that they are derived from adipose tissue. 
It is worth noting that despite this terminology, adipose tissue 
is not the sole source of most of these bioactive molecules, 
but such non-adipose sources are not of the present article’s 
scope. In this review we thus focus on the adipopharmacology 
of adipokines as related to obesity and associated diseases.
ADIPOKINES CONTRIBUTE TO SYSTEMIC INFLAMMATION 
AND RELATED DISEASES
Adipose tissue secretion of various endocrine adipokines 
contributes significantly to their circulating concentrations,
and the tissue expression and/or secretion of these adipokines 
also correlate with parameters of obesity and insulin resist-
ance. For example, the tissue secretion of adipokine IL-6 
may constitute up to a third of its plasma concentration in the 
absence of any acute inflammation (29). The protein levels
of IL-6 in abdominal subcutaneous adipose tissue are higher 
in obese compared to non-obese subjects (30), and its mRNA 
levels correlate positively with plasma insulin concentrations 
in non-diabetic subjects (31). The percentage of body fat as 
a measure of adiposity appears to account for the negative 
correlation between plasma IL-6 concentrations and measures 
of insulin sensitivity in non-diabetic subjects (3). Adipose 
tissue also appears to be an important source of plasma IL-8. 
IL-8 secretion by adipose tissue correlates with body mass 
index (BMI) (32), and thus may contribute significantly to the
elevated plasma IL-8 concentration in obese (33) and insulin 
resistant people (4). Human adipose tissue, particularly adi-
pocytes, selectively and highly expresses SAA (15); this may 
explain the correlation between its tissue mRNA and protein 
levels and serum concentrations (14). Similarly, adipose tissue 
mRNA transcript levels of adiponectin, an abundant adipokine 
produced predominantly by the tissue (34), correlate with its 
circulating concentrations (35). Adipose tissue mRNA and 
protein levels of MCP-1 correlate with its plasma concentra-
tions in animal models of obesity (36,37). Adipose-specific
overexpression of MCP-1 in transgenic mice increases its 
plasma concentrations and results in systemic insulin resistance 
(38). However, the relationship between MCP-1 expression 
levels in adipose tissue and its circulating concentrations in 
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human has not been fully elucidated. 
The expression and secretion of the above pro-inflamma-
tory endocrine adipokines may be enhanced by intercellular 
cross-talk in adipose tissue, such as the interaction between 
adipocytes and macrophages as an emerging important con-
stituent of the tissue stromovascular fraction. Recent studies 
demonstrate that the percentage of macrophages in adipose 
tissue correlates with obesity (39) and insulin resistance 
(40). The resident macrophages are derived from peripheral 
blood monocytes that infiltrate into adipose tissue (39). The
infiltration process begins with monocyte chemotaxis and
adhesion to adipose tissue (41). Once inside the adipose tis-
sue, the monocytes can differentiate into macrophages that 
have, among many other properties, enhanced inflammatory
activity (42), creating a pro-inflammatory loop within adipose
tissue through their secretion of TNF-α and IL-1β (43). Both 
cytokines further induce the transcription of  other pro-in-
flammatory factors, e.g. IL-6 and PAI-1(44). Tumor necrosis 
factor-α also increases adipose tissue expression levels of IL-8 
mRNA (45), while decreasing those of adiponectin (46,47). In 
addition, TNF-α stimulates free fatty acid release and insulin 
resistance in adipose tissue (48). These functions of adipokine 
TNF-α may help explain the associations between the expres-
sion levels of TNF-α in adipose tissue with measures of obes-
ity (49) and plasma insulin concentrations (31). A variety of 
other factors secreted by macrophages and potentially other 
cell types, such as mast cells (50), in adipose tissue may also 
modulate adipokine expression and secretion. 
MOLECULAR REGULATION OF ADIPOKINE EXPRESSION 
AND SECRETION
The expression and secretion of the above pro-inflammatory
adipokines may be modulated by various molecular factors, 
such as oxidative stress. Enhanced oxidative stress in adipose 
tissue is associated with accumulation of adipose tissue mass 
in obesity (51). The oxidative stress in adipose tissue is mani-
fested in increased reactive oxygen species (ROS) production, 
elevated expression levels of nicotinamide adenine dinucle-
otide phosphohydrogenase (NADPH) oxidase and decreased 
expression levels of anti-oxidative enzymes. Increased oxida-
tive stress in adipocytes as measured by ROS production may 
be mediated by different pathways, such as protein kinase C-δ 
(52) and hyperpolarization of the mitochondrial membrane 
(53). Oxidative stress contributes to adipose tissue inflamma-
tion as demonstrated by increased expression levels of IL-6, 
PAI-1, and MCP-1, and decreased levels of adiponectin (51) 
in adipocytes exposed to ROS generators such as H2O2 or 
xanthine oxidase. Increased expression and secretion of IL-6 
(53) and PAI-1 (54) by adipocytes due to ROS has also been 
demonstrated using other generators of ROS, such as hyper-
glycemia (53) and lipid peroxidation (54). Similarly, in vivo 
infusion of angiotensin II induces oxidative stress in adipose 
tissue as assessed by increased mRNA expression levels of 
NADPH oxidase components, resulting in decreased adiponec-
tin expression and secretion from adipose tissue (55). 
Oxidative stress in adipose tissue stimulates major mo-
lecular pro-inflammatory pathways, such as the ubiquitous
transcription factor nuclear factor kappa B (NF-κB) pathway 
(56). Modulated by inhibitor-κ B kinases (IKKα and IKKβ), 
NF-κB acts as a central regulator of pro-inflammatory response
that directly induces adipose tissue transcription of multiple 
genes encoding pro-inflammatory adipokines, including
IL-6 and IL-8 (57) (an extensive list of genes regulated by 
NF-κB has been compiled at http://bioinfo.lifl.fr/NF-KB/).
This regulation may be due in part to the fact that the basal 
activity of NF-κB increases during adipocyte differentiation 
from precursor cells (58). Elevated adipose tissue expression 
of paracrine adipokines regulated by NF-κB, such as MCP-1 
(38) and intercellular adhesion molecule 1 (ICAM-1) (59), may 
facilitate macrophage infiltration of the tissue. Furthermore,
resident macrophages may utilize the IKK/NF-κB pathway 
to augment the self-propagated cycle of inflammation in the
tissue, as this pathway appears to mediate the pro-inflamma-
tory effects of macrophage cytokines TNF-α and IL-1β on 
adipose tissue (57). 
In inducing the transcriptional activation of pro-inflamma-
tory genes, NF-κB requires assistance from other transcription 
factors, such as activating protein 1 (AP-1) (60). The activity 
of AP-1 transcription factors often depends on the activity of 
mitogen-activated protein kinase (MAPK) signaling pathway. 
The MAPK pathway consists of serine/threonine kinases; no-
tably, the mRNA expression levels of several kinases involved 
in this pathway are increased in adipose tissue from obese 
compared to lean subjects (61). There are three major groups 
of classical MAPKs: extracellular signal-regulated kinases 
(ERK) 1 and 2; c-Jun amino-terminal kinases (JNK) 1, 2, and 3; 
and p38 MAPK (p38) α, β, γ, and δ (62). The MAPK pathway 
may specifically contribute to the transcriptional regulation of
pro-inflammatory proteins in adipose tissue, because inhibitors
of this pathway decrease the tissue secretion of IL-6 (57), IL-8 
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(57), MCP-1 (63), and TNF-α (64). Furthermore, inhibition 
of both p38 MAPK and NF-κB pathways in adipose tissue 
reduces the secretion of MCP-1 to a greater extent compared to 
inhibition of NF-κB alone (63). In addition, activation of JNK, 
such as induced by obesity-related endoplasmic reticulum 
stress (65), may lead to insulin resistance and T2DM (65-67). 
Taken together, all of the above transcriptional pathways may 
serve as adipopharmacologic targets for current and new drugs 
to treat obesity-related diseases.
PHARMACOLOGIC AGENTS MODULATING ADIPOKINE EX-
PRESSION AND SECRETION
Given the important contribution of adipokines to various 
diseases as described above, regulation of their expression 
and secretion serves a therapeutic target. In fact, current ap-
proaches to prevent or treat the diseases may achieve their 
effects in part by reducing the expression and secretion of 
pro-inflammatory adipokines while stimulating those of anti-
inflammatory adipokines. These approaches include lifestyle
changes and pharmacologic intervention. The first approach
aims to modify behavior by means of diet and exercise, but 
such efforts typically result in modest outcomes (68). This is 
presumably due to short duration and/or minimal intensity of 
the treatments resulting in difficulties to achieve long-term
optimal weight maintenance. While the effects of these behav-
ior modifications on adipokine expression and secretion are
reviewed elsewhere (69; also see Kroff and E… in this volume 
of Biomedical Reviews), this review focuses on the second 
approach using pharmacologic agents. This latter approach 
is needed especially for those individuals who are unable or 
unwilling to change their lifestyle. 
Anti-oxidants. Despite the accumulating evidence for the 
role of oxidative stress in regulating adipokine expression and 
secretion as described above, data are scarce on medications 
targeting this specific pathway. Nevertheless, the anti-oxidant
property of several types of medications may contribute to 
their effects in improving adipokine-related diseases. For 
example, olmesartan, an angiotensin II type 1 (AT1) recep-
tor blocker used to treat hypertension, appears to ameliorate 
angiotensin II-induced dysregulation of adipokine secretion 
by reducing ROS and attenuating the expression of NADPH 
oxidase subunits in adipose tissue (70). This process may 
directly involve blockade of AT1 receptor because inhibition 
of angiotensin-converting enzyme by captopril appears to be 
less effective (70). Another class of medication, metformin, a 
dimethylbiguanide commonly used as an anti-diabetic agent 
(71), appears to have an anti-oxidant activity independent of 
its insulin-sensitizing effects (72). This anti-oxidative func-
tion may explain the effects of in vitro metformin treatment 
of adipose tissue in reducing the mRNA and protein levels 
of PAI-1 (73), IL-8 (74), and MCP-1 (75). Nevertheless, ad-
ministration of metformin to subjects with impaired glucose 
tolerance for 10 weeks does not appear to reduce the mRNA 
levels of MCP-1 or CD68, a macrophage marker, in adipose 
tissue (40). Further adipocentric studies are needed to clarify 
if metformin can regulate the expression and secretion of adi-
pokines in vivo, and if this potential effect is mediated by its 
anti-oxidative mechanisms. Similar potential effects of other 
anti-oxidative agents and/or supplements (e.g. β-carotene, 
vitamin E, ascorbate, N-acetylcysteine, etc.) on regulating 
adipokine expression and secretion need to be evaluated. 
Thiazolidinediones. Recent studies highlight the increas-
ingly recognized anti-inflammatory effects of thiazolidin-
ediones (TZDs), peroxisome proliferator-activated recep-
tor-gamma (PPAR-γ) agonists, on adipokine expression and 
secretion. These widely-used insulin sensitizing agents not 
only have direct anti-inflammatory effects on adipose tissue
(76), but also reduce markers of systemic inflammation, e.g.
by decreasing plasma concentrations of CRP and PAI- 1 (77, 
78). Exposure of adipocytes or adipose tissue to TZDs results 
in their reduced secretion of pro-inflammatory adipokines such
as PAI-1 (79), IL-6 (80), and IL-8 (74). Thiazolidinediones 
also reduce TNF-α-mediated transcription of genes encoding 
pro-inflammatory adipokines in adipocytes, presumably by an-
tagonizing NF-κB transcriptional regulation (81). In contrast, 
TZDs stimulate the mRNA expression levels of adiponectin 
and its subsequent secretion into circulation (82). In addition 
to modulating the expression and secretion of the above adi-
pokines, TZDs treatment of subjects with a wide range of BMI 
also decreases the level of macrophage infiltration in adipose
tissue, resulting in improved insulin sensitivity (83). 
The anti-inflammatory effects of TZDs are thought to be
mediated, at least in part, through the same mechanism used 
to achieve their insulin-sensitizing effects, i.e. via binding 
to PPAR-γ (81). Activation of PPAR-γ by troglitazone, a 
TZDs agent, interferes with NF-κB signaling in adipose tis-
sue and downregulates the transcription of pro-inflammatory
adipokines (81). In addition, rosiglitazone, another TZDs 
agent, suppresses the induction of MAPK pathway by TNF-α 
in adipocytes (84). These mechanisms may help explain the 
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efficacy of abscisic acid, a naturally occurring phytochemi-
cal with structural similarities to TZDs, in decreasing TNF-α 
mRNA levels and macrophage infiltration while stimulating
the transcription of adiponectin gene in adipose tissue (85). 
Despite their efficacy, TZDs are associated with a number
of side effects, e.g. weight gain and congestive heart failure 
(86). These effects have prompted efforts to search for novel 
PPAR-γ ligands, such as non-TZDs PPAR-agonists and se-
lective PPAR modulators (86). More studies are needed to 
determine the potential ability of these ligands to regulate 
adipokine expression and secretion. 
Statins. These agents constitute a different class of medi-
cation that may regulate adipokine expression and secretion 
by exerting anti-inflammatory effects. These potent inhibitors
of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) re-
ductase are widely used to reduce serum total cholesterol and 
low-density lipoprotein cholesterol levels and, thus, decrease 
the incidence of coronary heart disease (87). In addition, ce-
rivastatin has been shown to reduce mRNA and protein levels 
of IL-6 from adipocytes, presumably through inhibition of the 
NF-κB pathway (87). Atorvastatin, another statin, directly 
inhibits gene expression and secretion of IL-6 (88) and TNF-
α (89) from adipocytes as well as reduces their circulating 
concentrations in hypercholesterolemic rabbits. 
Other agents. There are other pharmacologic agents that 
interfere with adipose tissue NF-κB signaling pathway as 
well as other pro-inflammatory pathways such as MAPK as
described above; nevertheless, these agents are not currently 
used as medications to treat people in clinical settings. Such 
agents that have been shown to regulate adipokine expression 
and secretion include sulfasalazine and BAY 11-7082 (90). 
These agents decrease the release of IL-6, IL-8, and TNF-α 
from adipose tissue by reducing the protein expression of IKKβ 
and, thus, the activity of NF-κB DNA binding activity (90). 
Notably, sulfasalazine, a salicylate derivative, and salicylates 
have been shown to improve insulin sensitivity and glycemic 
control in obese rodents (91) and in people with T2DM (92). 
The side effects of high doses of aspirin, e.g. gastrointestinal 
bleeding (93), preclude prolonged usage of this medication; 
thus, current studies focus on the efficacy of other salicylate
derivatives in ameliorating insulin resistance. More studies 
are needed to determine the potential of these derivatives 
on regulating adipokine expression and secretion. Other 
pharmacologic agents targeting MAPK pathways also sup-
press pro-inflammatory adipokine secretion, as exemplified
by the ability of SB0025, a specific p38 MAPK inhibitor, to
partially reduce mRNA and protein levels of IL-6 and IL-8 in 
adipose tissue (57). Combination of SB0025 with a specific
NF-κB inhibitor, 6-amino-4-phenoxyphenethylaminoquinazo-
line, inhibits secretion of both adipokines to a greater extent 
(57). These in vitro data indicate the potential to develop 
pharmacologic agents for clinical use that inhibit the above 
pro-inflammatory pathways to regulate adipokine expression
and secretion. Such agents will help prevent and/or treat 
obesity-related diseases. 
CONCLUSION
Adipokine expression and secretion by adipocytes and other 
cells of adipose tissue can be regulated by pharmacologic 
agents with anti-inflammatory activity against molecular and
cellular contributors of adipose tissue inflammation. The ex-
act molecular mechanism(s) of these agents in differentially 
influencing the secretion of pro- versus anti-inflammatory
adipokines remains to be determined. Development of novel 
agents in the future that target both transcriptional and secre-
tory pathways in adipose cells may help ameliorate adipokine-
associated diseases (50,94,95). 
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